Víctor M. Diaz

This paper develops and validates a dual-targeting CAR-T cell therapy for T-ALL that targets CCR9 and CD1a, showing improved efficacy and safety compared to single-targeting approaches.

The paper introduces deep neural networks to infer bioactivity signatures for uncharacterized compounds, improving activity prediction across various biological endpoints.

The paper introduces Chemical Checker, a resource that integrates bioactivity data on 800,000 small molecules and demonstrates its use in drug discovery and disease modeling.